bit.bio expands Board of Directors with the Appointment of Entrepreneurs and a Nobel Laureate

Products You May Like

CAMBRIDGE, England — At the moment bit.bio welcomes three new members to its board of administrators, who convey their respective expertise of turning world class science into new industries and firm progress. The brand new administrators will present vital steering as bit.bio scales their proprietary artificial biology cell programming expertise platform, creating merchandise and options based mostly on human cells that may rework healthcare from fundamental analysis and drug discovery to subsequent technology cell based mostly therapies.

Hermann Hauser would be the chair of the board. He brings precious expertise in creating complete new industries and markets by means of groundbreaking applied sciences together with his expertise as co-founder of Arm Ltd. holdings, a world main UK laptop chip firm. As an early investor of Solexa (now Illumina), Dr. Hauser laid the inspiration for the continued artificial biology revolution with applied sciences to learn the human genome. He’s additionally a key member of the Cambridge science and expertise neighborhood, in addition to a trusted innovation advisor of the UK authorities. Dr. Hauser is a fellow of the Royal Society, KBE and co-founder of the enterprise capital agency Amadeus Capital Companions.

Hermann Hauser mentioned:

“I consider bit.bio is effectively positioned to turn out to be one of many defining firms within the artificial biology discipline, and I’m very excited to take the place of chair of the board. I see world altering potential of their expertise and stay up for bringing my expertise and experience to the management workforce. I need to see bit.bio develop into an iconic Cambridge firm, creating jobs and new industries, and most significantly, bringing the following technology of medicines to sufferers.”

Sir Gregory Winter is a Nobel prize successful scientist who invented applied sciences for making therapeutic monoclonal antibodies, and was instantly concerned of their industrial growth, notably by means of the beginning up firm Cambridge Antibody Know-how Ltd. His innovations underpin lots of the therapeutic antibodies in growth and available on the market, together with blockbuster medicine equivalent to Humira, Herceptin, Avastin and Keytruda. Extra just lately, by means of Bicycle Therapeutics, he has been serving to to develop one other invention – using bicyclic peptides as a platform for novel therapeutics.

Sir Gregory Winter mentioned:

“I believe we’re nonetheless within the foothills in relation to using human cells for therapeutic functions, and I’m excited to hitch bit.bio on their journey to the peaks. With entry to probably limitless numbers of human cells at outlined states of differentiation, we might accomplish that rather more for sufferers – whether or not researching tough to deal with, advanced ailments, screening potential medicine on human cells, or growing precision cell therapies at an reasonably priced price. And the opti-ox expertise appears to supply a sensible path to scale these peaks.”

Alan S. Roemer will convey his entrepreneurial experience from the biotechnology sector to bit.bio. As a life sciences government and board director, he’ll supply significant capital markets and operational enterprise constructing expertise to make sure that bit.bio is well-financed and well-positioned to scale. Mr. Roemer has launched three multi-billion greenback biotechnology firms, raised over $1.75 billion in non-public and public capital, and consummated 5 IPOs. He was a founding management workforce member of Pharmasset (acquired by Gilead Sciences for $11 billion ) and Roivant Sciences, an organization growing progressive medicines by means of a novel type of industrial organisation in R&D. His expertise at Roivant is especially related to bit.bio’s technique to construct its cell coding expertise opti-ox into a number of verticals the place human cells are utilized to analysis, drug discovery and cell therapies. Along with serving as a member of the board, Mr. Roemer will chair the audit and compensation committees.

Alan Roemer mentioned:

“bit.bio is at that thrilling stage of progress and evolution that I’ve been by means of a number of instances earlier than. It fuels my entrepreneurial spirit with the ‘enjoyable issue’ of firm enlargement and cultural influence. I’m excited to assist the management workforce ‘see round corners’ utilizing my expertise from my different high-growth firms. Most significantly, I need to present significant steering to finance and scale the enterprise, exploit the complete potential of bit.bio’s core expertise and have the potential to positively influence sufferers’ lives.”

Mark Kotter, founder and CEO of bit.bio mentioned:

“I’m humbled to be bringing collectively three world leaders in science, entrepreneurship and trade making for the board of bit.bio. The experience and expertise our new board will convey to the corporate will give our expertise one of the best probability to remodel healthcare for each affected person, in all places.”

– ENDS –

About bit.bio
Accelerated biomedical analysis, new generations of cures, elevated world sustainability. These are in attain when biology transitions to engineering.

At bit.bio, we work relentlessly to realize this aim. We mix the ideas of coding and biology to supply human cells for analysis, drug discovery, and a brand new technology of medicines.

For extra info go to bit.bio